Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases

Abstract

Older generation antihistamines are empirically used in subjects with UACS, however the data about their efficacy share conflicting evidence. The effect on cough is believed to be mediated via antihistamine, anticholinergic and central sedative effects. Nowadays, attention is given to the new categories of histamine receptor antagonists (H4), which are abundantly expressed on the immune cells, nasal nerves and glands, decreasing severity of nasal inflammation. The aim of our study was to assess the efficacy of H4 receptor antagonist JNJ 7777120 (JNJ) on nasal symptoms magnitude and cough in ovalbumine (OVA) induced allergic rhinitis in guinea pigs.Animals (n=15) were sensitized by intraperitoneal administration of OVA. Animals were repeatedly challenged with nasal OVA to induce allergic rhinitis and up-regulate cough reflex. When the reliability of the model was confirmed, animals were pretreated with JNJ (0.25 mg/kg and 0.5 mg/kg i.p. 30 minutes prior OVA administration). Cough was induced by inhalation of citric acid 0.4 M, for 10 minutes. Final count of coughs was confirmed using traces of sudden interruption of the basal breathing by cough pattern.Allergic rhinitis up regulated the cough response from 11±2 to 19±3 cough per provocation, med±IQR, p <0.05. Pretreatment with 0.25 mg/kg showed a tendency to decrease cough responsiveness and suppress nasal symptoms, however the data did not reach significance. Dose 0.5 mg/kg significantly suppressed the nasal symptoms, and number of cough obtained during provocation from 19±3 to 10±1, med±IQR, p <0.05.Conclusion: JNJ in a dose 0.5mg/kg significantly suppressed the rhinitis symptoms and cough induced by citric acid.

Rating:

Share or cite this content

Citations should be made in the following way:
E. Kovacova, S. Gavliakova, M. Brozmanova, T. Buday, J. Plevkova (Martin, Slovakia). H4 receptor antagonits as a potential medication for upper airway cough syndrom. Eur Respir J 2014; 44: Suppl. 58, 1513

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma. Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Side effects of the leukotriene receptor antagonists in asthmatic children Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Expression of CysLT2 receptors in asthmatic lung, and the roles in bronchoconstriction Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Long-acting beta2 agonist without concomitant inhaled corticosteroids in children with asthma in primary care Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Comparison of three modalities of corticosteroids administration in chronic rhinosinusitis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 LATE-BREAKING ABSTRACT: Attenuation of allergen-induced asthmatic responses by inhaled GATA-3 specific DNAzyme Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Can forced oscillation technique parameters predict airway hyperresponsiveness to histamine? Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Clinical effectiveness of anti-IgE therapy in severe asthma with fungus sensitization Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Codeine for treatment of cough variant asthma Source: International Congress 2016 – Asthma points to ponder Year: 2016 Species comparison of interleukin-13 induced airway hyperreactivity as model for allergic asthma Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014